Published online Jan 18, 2023. doi: 10.5312/wjo.v14.i1.23
Peer-review started: September 14, 2022
First decision: October 17, 2022
Revised: October 20, 2022
Accepted: December 13, 2022
Article in press: December 13, 2022
Published online: January 18, 2023
Processing time: 121 Days and 2.4 Hours
Osteoarthritis (OA) is the most common joint disorder, is associated with an increasing socioeconomic impact owing to the ageing population.
To analyze and compare the efficacy and safety of bone-marrow-derived mesenchymal stromal cells (BM-MSCs) and adipose tissue-derived MSCs (AD-MSCs) in knee OA management from published randomized controlled trials (RCTs).
Independent and duplicate electronic database searches were performed, including PubMed, EMBASE, Web of Science, and Cochrane Library, until August 2021 for RCTs that analyzed the efficacy and safety of AD-MSCs and BM-MSCs in the management of knee OA. The visual analog scale (VAS) score for pain, Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), Lysholm score, Tegner score, magnetic resonance observation of cartilage repair tissue score, knee osteoarthritis outcome score (KOOS), and adverse events were analyzed. Analysis was performed on the R-platform using OpenMeta (Analyst) software. Twenty-one studies, involving 936 patients, were included. Only one study compared the two MSC sources without patient randomization; hence, the results of all included studies from both sources were pooled, and a comparative critical analysis was performed.
At six months, both AD-MSCs and BM-MSCs showed significant VAS improvement (P = 0.015, P = 0.012); this was inconsistent at 1 year for BM-MSCs (P < 0.001, P = 0.539), and AD-MSCs outperformed BM-MSCs compared to controls in measures such as WOMAC (P < 0.001, P = 0.541), Lysholm scores (P = 0.006; P = 0.933), and KOOS (P = 0.002; P = 0.012). BM-MSC-related procedures caused significant adverse events (P = 0.003) compared to AD-MSCs (P = 0.673).
Adipose tissue is superior to bone marrow because of its safety and consistent efficacy in improving pain and functional outcomes. Future trials are urgently warranted to validate our findings and reach a consensus on the ideal source of MSCs for managing knee OA.
Core Tip: With the ongoing rise in the exploration of the clinical efficacy of mesenchymal stromal cells (MSCs) in the management of osteoarthritis (OA), there is an imminent need to identify the ideal source of MSCs to be utilized. Our meta-analysis has brought out the lacunae in the literature for studies to evaluate the impact of the source of MSCs in the management of OA. From a single-arm meta-analysis of available studies on the two commonly used sources such as bone marrow (BM) and adipose tissue, we found the adipose tissue to be superior to BM concerning the safety and consistent efficacy in improving pain and functional outcomes. However, considering the paucity of evidence, we recommend future trials to validate our findings and reach a consensus on the ideal source of MSCs for managing knee OA.